10月15日，一品红盘中上涨2.06%，截至10:04，报54.07元/股，成交1.59亿元，换手率0.71%，总市值 244.23亿元。 资金流向方面，主力资金净流出2468.63万元，特大单买入476.11万元，占比3.00%，卖出369.44万元， 占比2.33%；大单买入2375.54万元，占比14.98%，卖出4950.83万元，占比31.22%。 一品红今年以来股价涨216.94%，近5个交易日跌9.02%，近20日跌21.13%，近60日跌11.16%。 今年以来一品红已经5次登上龙虎榜，最近一次登上龙虎榜为7月21日，当日龙虎榜净买入6557.61万 元；买入总计3.05亿元 ，占总成交额比20.96%；卖出总计2.40亿元 ，占总成交额比16.46%。 一品红所属申万行业为：医药生物-化学制药-化学制剂。所属概念板块包括：抗流感、医药电商、猴痘 概念、肝炎治疗、中药等。 截至9月30日，一品红股东户数1.89万，较上期减少11.34%；人均流通股22055股，较上期增加12.79%。 2025年1月-6月，一品红实现营业收入5.84亿元，同比减少36.02%；归母净利润-7354.22万元， ...

资料显示，一品红药业集团股份有限公司位于广东省广州市黄埔区广州国际生物岛寰宇一路27号云润大 厦15-19层，成立日期2002年2月4日，上市日期2017年11月16日，公司主营业务涉及自有药品的研发、 生产和销售及代理药品的销售。主营业务收入构成为：儿童药61.12%，慢病药22.71%，其他16.17%。 10月13日，一品红涨5.35%，截至发稿，报61.40元/股，成交3.74亿元，换手率1.50%，总市值277.34亿 元。 华宝医药生物混合A（240020）基金经理为张金涛。 截至发稿，张金涛累计任职时间9年356天，现任基金资产总规模12.02亿元，任职期间最佳基金回报 62.24%， 任职期间最差基金回报-14.23%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 责任编辑：小浪快报 从基金十大重仓股角度 数据显示，华宝基金旗下1只基金重仓一品红。华宝医药生物混合A（240020）二季度持有股数37.3万 股，占基金净值比例为3.59%，位居第九大重仓 ...

10月9日，一品红跌5.01%，截至发稿，报56.45元/股，成交3.12亿元，换手率1.29%，总市值254.98亿 元。 资料显示，一品红药业集团股份有限公司位于广东省广州市黄埔区广州国际生物岛寰宇一路27号云润大 厦15-19层，成立日期2002年2月4日，上市日期2017年11月16日，公司主营业务涉及自有药品的研发、 生产和销售及代理药品的销售。主营业务收入构成为：儿童药61.12%，慢病药22.71%，其他16.17%。 从基金十大重仓股角度 数据显示，中信建投基金旗下1只基金重仓一品红。中信建投远见回报A（011868）二季度持有股数9.5 万股，占基金净值比例为0.91%，位居第一大重仓股。根据测算，今日浮亏损失约28.31万元。 中信建投远见回报A（011868）基金经理为谢玮。 截至发稿，谢玮累计任职时间7年129天，现任基金资产总规模19.87亿元，任职期间最佳基金回报 106.5%， 任职期间最差基金回报-20.05%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不 ...

Company Overview - Yipinhong Pharmaceutical Group Co., Ltd. is located in Guangzhou, Guangdong Province, and was established on February 4, 2002. The company was listed on November 16, 2017. Its main business involves the research, production, and sales of proprietary drugs, as well as the sales of agency drugs [1][2]. Financial Performance - As of August 31, Yipinhong reported a revenue of 584 million yuan for the first half of 2025, a year-on-year decrease of 36.02%. The net profit attributable to shareholders was -73.54 million yuan, a year-on-year decrease of 258.30% [2]. - The company has cumulatively distributed 335 million yuan in dividends since its A-share listing, with 151 million yuan distributed over the past three years [3]. Stock Performance - On September 25, Yipinhong's stock price decreased by 2.00%, trading at 58.30 yuan per share, with a total market capitalization of 26.334 billion yuan. The stock has increased by 241.74% year-to-date but has seen a decline of 4.06% in the last five trading days and 11.84% in the last 20 days [1]. - The stock has appeared on the "龙虎榜" (a stock trading list) five times this year, with the most recent appearance on July 21, where it recorded a net purchase of 65.576 million yuan [1]. Shareholder Information - As of August 31, the number of shareholders for Yipinhong was 21,400, an increase of 0.49% from the previous period. The average circulating shares per person decreased by 0.49% to 19,553 shares [2]. - As of June 30, 2025, the eighth largest circulating shareholder is E Fund Medical Healthcare Industry Mixed A, holding 4.3661 million shares as a new shareholder, while Hong Kong Central Clearing Limited has exited the top ten circulating shareholders [3]. Industry Classification - Yipinhong belongs to the pharmaceutical and biological industry, specifically in the chemical pharmaceutical sector, with concepts including anti-influenza, pharmaceutical e-commerce, hepatitis treatment, monkeypox concept, and traditional Chinese medicine [2].

Core Viewpoint - Yipinhong's stock price has shown significant volatility, with a year-to-date increase of 252.81%, but recent declines in the short term raise questions about future performance [1][2]. Company Overview - Yipinhong Pharmaceutical Group Co., Ltd. is located in Guangzhou, Guangdong Province, and was established on February 4, 2002, with its listing date on November 16, 2017 [1]. - The company's main business involves the research, production, and sales of its own pharmaceuticals, as well as the sales of agent pharmaceuticals [1]. - The revenue composition is as follows: Children's medicine 61.12%, Chronic disease medicine 22.71%, Others 16.17% [1]. Financial Performance - For the first half of 2025, Yipinhong reported operating revenue of 584 million yuan, a year-on-year decrease of 36.02%, and a net profit attributable to shareholders of -73.54 million yuan, a year-on-year decrease of 258.30% [2]. - The company has distributed a total of 335 million yuan in dividends since its A-share listing, with 151 million yuan distributed in the last three years [3]. Shareholder Information - As of August 31, the number of Yipinhong's shareholders was 21,400, an increase of 0.49% from the previous period, with an average of 19,553 circulating shares per person, a decrease of 0.49% [2]. - As of June 30, 2025, Yipinhong's top ten circulating shareholders included E Fund Medical Healthcare Industry Mixed A as the eighth largest shareholder, holding 4.3661 million shares, while Hong Kong Central Clearing Limited exited the top ten list [3]. Market Activity - On September 24, Yipinhong's stock price rose by 2.02% to 60.19 yuan per share, with a trading volume of 218 million yuan and a turnover rate of 0.88%, resulting in a total market capitalization of 27.187 billion yuan [1]. - The stock has appeared on the "Dragon and Tiger List" five times this year, with the most recent appearance on July 21, where it recorded a net purchase of 65.5761 million yuan [1].

Group 1 - The core viewpoint of the articles indicates that Yipin Hong's stock has experienced significant fluctuations, with a year-to-date increase of 249.06% but a recent decline in the last five and twenty trading days [1][2] - As of August 31, the number of shareholders for Yipin Hong increased to 21,400, with an average of 19,553 circulating shares per person, reflecting a slight decrease [2] - The company reported a revenue of 584 million yuan for the first half of 2025, representing a year-on-year decrease of 36.02%, and a net profit loss of 73.54 million yuan, a decline of 258.30% [2] Group 2 - Yipin Hong has a total market capitalization of 26.898 billion yuan, with a trading volume of 137 million yuan and a turnover rate of 0.54% as of September 19 [1] - The company has been listed on the Dragon and Tiger list five times this year, with the most recent net purchase of 65.576 million yuan on July 21 [1] - The main business revenue composition of Yipin Hong includes 61.12% from children's medicine, 22.71% from chronic disease medicine, and 16.17% from other products [1][2] Group 3 - Since its A-share listing, Yipin Hong has distributed a total of 335 million yuan in dividends, with 151 million yuan in the last three years [3] - As of June 30, 2025, Yipin Hong's top ten circulating shareholders include a new entry, E Fund Medical Healthcare Industry Mixed A, holding 4.3661 million shares [3]

9月16日，一品红盘中下跌2.06%，截至10:13，报60.93元/股，成交1.24亿元，换手率0.48%，总市值 275.22亿元。 资金流向方面，主力资金净流出1741.82万元，特大单买入259.43万元，占比2.10%，卖出703.22万元， 占比5.68%；大单买入1980.41万元，占比16.00%，卖出3278.45万元，占比26.48%。 一品红今年以来股价涨257.15%，近5个交易日跌11.13%，近20日跌14.83%，近60日涨19.56%。 一品红所属申万行业为：医药生物-化学制药-化学制剂。所属概念板块包括：抗流感、医药电商、肝炎 治疗、中药、猴痘概念等。 截至8月31日，一品红股东户数2.14万，较上期增加0.49%；人均流通股19553股，较上期减少0.49%。 2025年1月-6月，一品红实现营业收入5.84亿元，同比减少36.02%；归母净利润-7354.22万元，同比减少 258.30%。 分红方面，一品红A股上市后累计派现3.35亿元。近三年，累计派现1.51亿元。 机构持仓方面，截止2025年6月30日，一品红十大流通股东中，易方达医疗保健行业混合A（110023） ...

Group 1 - The core viewpoint of the news is that Yipinhong Pharmaceutical Group experienced a decline in stock price, with a drop of 5.41% to 58.10 CNY per share, and a total market capitalization of 26.243 billion CNY [1] - Yipinhong's main business involves the research, production, and sales of its own pharmaceuticals, as well as the sales of agent pharmaceuticals, with revenue composition being 61.12% from children's medicine, 22.71% from chronic disease medicine, and 16.17% from other products [1] Group 2 - From the perspective of fund holdings, one fund under CITIC Jiantou has Yipinhong as its top holding, with 95,000 shares, accounting for 0.91% of the fund's net value [2] - The CITIC Jiantou Yuanjian Return A fund has a current scale of 430 million CNY and has achieved a year-to-date return of 28.48%, ranking 2387 out of 8175 in its category [2] - The fund manager, Xie Wei, has a tenure of 7 years and 101 days, with the best fund return during his tenure being 114.91% [2]

Group 1 - The core viewpoint of the news is that Yipinhong Pharmaceutical Group Co., Ltd. has shown a significant stock price increase of 5.23%, reaching 70.19 CNY per share, with a total market capitalization of 31.704 billion CNY [1] - Yipinhong's main business includes the research, production, and sales of its own pharmaceuticals, as well as the sales of agent pharmaceuticals, with revenue composition being 61.12% from children's medicine, 22.71% from chronic disease medicine, and 16.17% from other products [1] Group 2 - According to fund data, Nord Fund has a significant holding in Yipinhong, with the Nord Small and Mid-Cap Mixed Fund (570006) holding 27,000 shares, accounting for 4.49% of the fund's net value, ranking as the tenth largest holding [2] - The Nord Small and Mid-Cap Mixed Fund has achieved a year-to-date return of 52.57%, ranking 541 out of 8248 in its category, and a one-year return of 53.23%, ranking 2182 out of 8051 [2] Group 3 - The fund manager of the Nord Small and Mid-Cap Mixed Fund is Zhu Mingrui, who has been in the position for 3 years and 68 days, with the fund's total asset size being 70.9838 million CNY [3] - During Zhu Mingrui's tenure, the best fund return was 43.58%, while the worst return was -6.35% [3]

Core Viewpoint - The stock of Yipinhong has experienced significant fluctuations, with a year-to-date increase of 299.24%, but a recent decline in the last five and twenty trading days [1][2]. Group 1: Stock Performance - As of August 26, Yipinhong's stock price was 68.11 CNY per share, with a market capitalization of 30.765 billion CNY [1]. - The stock has seen a recent decline of 4.79% over the last five trading days and 8.85% over the last twenty trading days, despite a 31.41% increase over the last sixty days [1]. - The stock has appeared on the "Dragon and Tiger List" five times this year, with the most recent appearance on July 21, where it recorded a net purchase of 65.576 million CNY [1]. Group 2: Financial Performance - For the first half of 2025, Yipinhong reported a revenue of 584 million CNY, a year-on-year decrease of 36.02%, and a net profit attributable to shareholders of -73.5422 million CNY, a decrease of 258.30% [2]. - The company has distributed a total of 335 million CNY in dividends since its A-share listing, with 151 million CNY distributed in the last three years [3]. Group 3: Shareholder Information - As of July 31, the number of Yipinhong's shareholders increased to 21,300, a rise of 24.22%, while the average circulating shares per person decreased by 19.50% to 19,650 shares [2]. - Among the top ten circulating shareholders, E Fund Medical Healthcare Industry Mixed A (110023) is the eighth largest shareholder, holding 4.3661 million shares as a new entrant [3].